Navigation Links
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
Date:5/20/2009

- The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in 2010 -

SAN FRANCISCO, May 20 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from the first phase 3 clinical trial for lurasidone, which is under clinical development globally, for the treatment of patients with schizophrenia. In this six-week, double-blind, placebo-controlled trial, lurasidone 80 mg/day was significantly more effective than placebo for the treatment of acute schizophrenia. In addition, lurasidone was well-tolerated and had a relatively low discontinuation rate. The findings were presented at the 162nd Annual Meeting of the American Psychiatric Association in San Francisco, held on May 16-21.

PEARL 1 (Program to Evaluate the Antipsychotic Response to Lurasidone) is part of an extensive worldwide phase 3 clinical development program, involving more than 2,000 patients, intended to evaluate the safety and efficacy of lurasidone for the treatment of schizophrenia. In addition to the primary finding that lurasidone 80 mg/day was significantly more effective than placebo at the study endpoint, lurasidone was associated with greater improvement on both the Positive and Negative Syndrome Scale (PANSS) total score (primary endpoint) and the Clinical Global Impressions Severity scale (CGI-S, key secondary endpoint) at all visits between weeks two and six. PEARL 1 also evaluated two other fixed doses of lurasidone, 40 mg/day and 120 mg/day, which did not demonstrate separation from placebo on the PANSS or CGI-S at study endpoint.

"People with schizophrenia need new treatment options that offer a combination of efficacy, safety and tolerability so that the symptoms can be stabilized and effectively treated," said Henry Nasrallah, M.D., professor of psychiatry and neuroscience and director of the schizophrenia rese
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... 2014 Sanomedics International Holdings, Inc. (OTCQB: SIMH) ... Research & Data Services, demand for thermometers is expected ... 2018, as demand for more accurate digital thermometers continues.  ... world,s largest market for thermometers, and one of the ... International Holdings, Inc. Sanomedics International Holdings designs, ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS ; ... financial results for the fiscal 2011 second quarter ended December ... 2011. Management has scheduled a conference call ... 2011 (Tuesday, February 15 at 8:30 a.m. AEDT) , ...
... ST. LOUIS, Feb. 4, 2011 K-V Pharmaceutical Company ... today that it has been informed by Hologic, Inc. ... approval for Makena™ (hydroxyprogesterone caproate injection).  Makena, commonly referred ... treatment indicated to reduce the risk of preterm birth ...
Cached Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal 2011 Second Quarter on Monday, February 14, 2011 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 2FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 3FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 4FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 5FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 6FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 7FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 8FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 9FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 10FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 11FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth 12
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... increasingly important method for detecting malaria. Health specialists recommend ... other strategies for controlling the disease // , including ... indoor spraying against malaria-carrying mosquitoes and testing and treatment ... tests are ideal for rural areas are accurate, easy ...
... Researchers find that aspirin saves the life of cancer ... believe that majority of these patients will die// if ... turns common medical assumptions upside down and will likely ... thin blood and cancer patients experience low platelet counts ...
... The experts in this weeks' BMJ, have reported that ... work together to restore faith in drug development//. ... drug Vioxx, produced by Merck and Co. Inc., has ... be open to abuse. ,Vioxx (rofecoxib) ...
... explains - how beneficial traits accumulate in natural populations, but ... two theories have addressed this problem. The theory of hitchhiking ... can become common in natural populations when they "hitch a ... selection. ,Conversely, the theory of kin selection ...
... Drugs that Facilitate and/or Prevent Diabetes//. ... develop new-onset diabetes than those who don’t have hypertension, ... recent weight gain, or stronger family history of diabetes ... have known since 1958 that some drugs used to ...
... children with persistent fluid in the middle ear// need not ... , It is generally believed that ear fluid has to ... study suggests that inserting ear tubes to remove ear fluid ... years of age. This important study was conducted at Children’s ...
Cached Medicine News:Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3Health News:Aspirin Saves Life Even in Cancer Patients 2Health News:Aspirin Saves Life Even in Cancer Patients 3Health News:New Approach Needed To Restore Faith in Pharmaceutical Industry 2Health News:Study Explains How Costly Traits Evolve 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 2Health News:Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified 3Health News:Ear Fluid Does Not Impair Development 2Health News:Ear Fluid Does Not Impair Development 3Health News:Ear Fluid Does Not Impair Development 4
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
... of single-use products to promote safety for ... single-use catheter reduces cross-contamination and helps protect ... and, because cleaning is eliminated, you have ... have water perfused manometric catheters for esophageal, ...
... Air-Charged Catheters make motility ... Disposable Latitude catheters set up ... cross-contamination. And with every sensor ... by eliminating anatomical irregularities. For ...
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Medicine Products: